LB Pharmaceuticals (NASDAQ:LBRX) Price Target Raised to $60.00

LB Pharmaceuticals (NASDAQ:LBRX) had its target price hoisted by HC Wainwright from $45.00 to $60.00 in a report released on Monday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q3 2026 earnings at ($1.52) EPS, Q4 2026 earnings at ($1.49) EPS, FY2026 earnings at ($5.47) EPS, Q1 2027 earnings at ($1.55) EPS, Q2 2027 earnings at ($1.34) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($1.31) EPS and FY2027 earnings at ($5.48) EPS.

Other equities analysts also recently issued research reports about the company. BMO Capital Markets upped their target price on LB Pharmaceuticals from $46.00 to $54.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Piper Sandler reissued an “overweight” rating and set a $78.00 price target on shares of LB Pharmaceuticals in a report on Monday, August 3rd. Weiss Ratings downgraded LB Pharmaceuticals from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday, August 11th. Wolfe Research initiated coverage on LB Pharmaceuticals in a report on Tuesday, July 7th. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Wall Street Zen cut LB Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.62.

LB Pharmaceuticals Price Performance

Shares of LBRX opened at $48.17 on Monday. The company’s 50-day moving average is $38.10 and its 200-day moving average is $30.88. The firm has a market capitalization of $1.55 billion and a PE ratio of -14.00. LB Pharmaceuticals has a fifty-two week low of $13.36 and a fifty-two week high of $50.16.

LB Pharmaceuticals (NASDAQ:LBRX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.87). Analysts predict that LB Pharmaceuticals will post -5.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LB Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Deep Track Capital LP acquired a new stake in shares of LB Pharmaceuticals during the 3rd quarter worth approximately $52,941,000. RA Capital Management L.P. raised its position in LB Pharmaceuticals by 24.3% during the fourth quarter. RA Capital Management L.P. now owns 2,208,604 shares of the company’s stock valued at $49,164,000 after purchasing an additional 431,646 shares in the last quarter. TCG Crossover Management LLC acquired a new position in LB Pharmaceuticals during the third quarter valued at approximately $27,554,000. JPMorgan Chase & Co. lifted its stake in LB Pharmaceuticals by 56.1% during the fourth quarter. JPMorgan Chase & Co. now owns 1,611,482 shares of the company’s stock worth $35,872,000 after purchasing an additional 578,879 shares during the last quarter. Finally, Spruce Street Capital LP boosted its holdings in shares of LB Pharmaceuticals by 36.9% in the 1st quarter. Spruce Street Capital LP now owns 1,376,159 shares of the company’s stock valued at $33,645,000 after purchasing an additional 370,566 shares in the last quarter.

Trending Headlines about LB Pharmaceuticals

Here are the key news stories impacting LB Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $60 target price, suggesting analysts still see upside from the recent $48-area trading level. HC Wainwright rating and price target
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 25, unchanged from August 10, with a zero-day days-to-cover ratio. Because the data appears inconsistent, it provides no meaningful indication of short-selling pressure. LB Pharmaceuticals short-interest report
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across nearly every period. Q3 2026 estimates fell to -$1.52 from -$0.95, Q4 2026 to -$1.49 from -$1.07, and fiscal 2026 to -$5.47 from -$3.51. Fiscal 2027 estimates declined to -$5.48 from -$4.87, with smaller reductions across each quarter. The revisions indicate expectations for deeper or more prolonged losses. HC Wainwright LB Pharmaceuticals earnings estimates

LB Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.